Federated Hermes’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,440
| Closed | -$84.6K | – | 2183 |
|
|
2023
Q4 | $84.6K | Buy |
+1,440
| New | +$81K | ﹤0.01% | 1598 |
|
|
2023
Q1 | – | Sell |
-25
| Closed | -$1.13K | – | 2300 |
|
|
2022
Q4 | $1.13K | Sell |
25
-260,245
| -100% | -$16.8M | ﹤0.01% | 2051 |
|
|
2022
Q3 | $18.2M | Sell |
260,270
-4,886
| -2% | -$362K | 0.05% | 403 |
|
|
2022
Q2 | $17.8M | Buy |
265,156
+5,949
| +2% | +$378K | 0.05% | 414 |
|
|
2022
Q1 | $21.3M | Buy |
259,207
+359
| +0.1% | +$36.7K | 0.05% | 423 |
|
|
2021
Q4 | $38M | Buy |
258,848
+103,448
| +67% | +$16.1M | 0.07% | 332 |
|
|
2021
Q3 | $27.5M | Buy |
155,400
+700
| +0.5% | +$113K | 0.05% | 411 |
|
|
2021
Q2 | $25M | Sell |
154,700
-2,139
| -1% | -$343K | 0.05% | 433 |
|
|
2021
Q1 | $26.9M | Sell |
156,839
-85,113
| -35% | -$16.9M | 0.05% | 422 |
|
|
2020
Q4 | $53.1M | Buy |
241,952
+30,267
| +14% | +$6.54M | 0.11% | 237 |
|
|
2020
Q3 | $35.1M | Buy |
211,685
+33,735
| +19% | +$4.62M | 0.08% | 281 |
|
|
2020
Q2 | $20.3M | Buy |
177,950
+162,849
| +1,078% | +$15.8M | 0.05% | 390 |
|
|
2020
Q1 | $1.16M | Buy |
15,101
+11,782
| +355% | +$1.06M | ﹤0.01% | 1081 |
|
|
2019
Q4 | $428K | Sell |
3,319
-35,245
| -91% | -$3.4M | ﹤0.01% | 1480 |
|
|
2019
Q3 | $3M | Sell |
38,564
-61,480
| -61% | -$5.77M | 0.01% | 908 |
|
|
2019
Q2 | $10.3M | Sell |
100,044
-49,483
| -33% | -$3.85M | 0.03% | 576 |
|
|
2019
Q1 | $11M | Buy |
149,527
+71,255
| +91% | +$4.85M | 0.03% | 530 |
|
|
2018
Q4 | $3.32M | Sell |
78,272
-42,045
| -35% | -$1.68M | 0.01% | 850 |
|
|
2018
Q3 | $5.67M | Buy |
120,317
+86,218
| +253% | +$4.8M | 0.01% | 771 |
|
|
2018
Q2 | $1.68M | Buy |
34,099
+29,875
| +707% | +$1.13M | ﹤0.01% | 1091 |
|
|
2018
Q1 | $130K | Sell |
4,224
-6,344
| -60% | -$176K | ﹤0.01% | 1565 |
|
|
2017
Q4 | $193K | Sell |
10,568
-9,001
| -46% | -$140K | ﹤0.01% | 1524 |
|
|
2017
Q3 | $229K | Sell |
19,569
-678
| -3% | -$3.92K | ﹤0.01% | 1481 |
|
|
2017
Q2 | $74K | Buy |
20,247
+19,425
| +2,363% | +$74.4K | ﹤0.01% | 1615 |
|
|
2017
Q1 | $4K | Sell |
822
-526
| -39% | -$2.88K | ﹤0.01% | 1982 |
|
|
2016
Q4 | $6K | Buy |
+1,348
| New | +$7.33K | ﹤0.01% | 1919 |
|
|
2015
Q2 | – | Sell |
-316
| Closed | -$9K | – | 2092 |
|
|
2015
Q1 | $9K | Buy |
+316
| New | +$7.41K | ﹤0.01% | 1796 |
|
Other funds holding MRTX
Federated Hermes's MRTX Position: Q1 2024 in Review
Federated Hermes sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,440 shares — an estimated $84.6K sold.
Federated Hermes first reported a position in MRTX in Q1 2015 and held it in 27 quarters. The position peaked at $53.1M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Federated Hermes reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Federated Hermes sold 1,440 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $84.6K.
- Federated Hermes first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 27 quarters.
- Federated Hermes's Mirati Therapeutics, Inc. Common Stock position peaked at $53.1M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.